Invitae Hereditary Pediatric Solid Tumors Panel
Use
The Invitae Pediatric Solid Tumors Panel analyzes genes associated with childhood-onset tumors. Due to genetic heterogeneity, broad panel testing evaluates several genes based on a single clinical indication. It assists in confirming clinical diagnosis, predicting disease progression, facilitating early symptom detection, informing family planning, genetic counseling, and possibly enrolling in clinical trials.
Special Instructions
This test is designed for heritable germline mutations and is not suitable for detecting somatic mutations in tumor tissue. Some genes may relate to other disorders, not included in the test's scope. Variants such as structural rearrangements might not be detected due to complex sequence architecture.
Limitations
Single nucleotide variants and small indels are detected with high sensitivity, but detection of larger insertions or complex variants may be marginally reduced. Certain types of mosaicism, phasing, or mapping ambiguities might not be fully resolved. Some promoter and non-coding sequence changes are not covered. DNA from recent transfusions may not represent the patient genome accurately.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3mL
Minimum Volume
Not provided
Container
purple-top EDTA tube (K2EDTA or K3EDTA)